153 related articles for article (PubMed ID: 10978264)
1. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.
Merlini PA; Ardissino D; Rosenberg RD; Colombi E; Agricola P; Oltrona L; Ottani F; Galvani M; Bauer KA; Bottasso B; Bertocchi F; Mannucci PM
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2162-6. PubMed ID: 10978264
[TBL] [Abstract][Full Text] [Related]
2. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
3. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
Kottke-Marchant K; Bahit MC; Granger CB; Zoldhelyi P; Ardissino D; Brooks L; Griffin JH; Potthoff RF; Van de Werf F; Califf RM; Topol EJ
Eur Heart J; 2002 Aug; 23(15):1202-12. PubMed ID: 12127922
[TBL] [Abstract][Full Text] [Related]
4. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
6. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Yusuf S
Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
[TBL] [Abstract][Full Text] [Related]
7. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Topol EJ; Fuster V; Harrington RA; Califf RM; Kleiman NS; Kereiakes DJ; Cohen M; Chapekis A; Gold HK; Tannenbaum MA
Circulation; 1994 Apr; 89(4):1557-66. PubMed ID: 8149521
[TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
[TBL] [Abstract][Full Text] [Related]
9. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
[TBL] [Abstract][Full Text] [Related]
10. Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model: time course and effect of hirudin.
Barry WL; Gimple LW; Humphries JE; Powers ER; McCoy KW; Sanders JM; Owens GK; Sarembock IJ
Circulation; 1996 Jul; 94(1):88-93. PubMed ID: 8964123
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
Circulation; 1994 Oct; 90(4):1631-7. PubMed ID: 7923645
[TBL] [Abstract][Full Text] [Related]
12. Recombinant hirudins: an overview of recent developments.
Zeymer U
BioDrugs; 1998 Dec; 10(6):425-36. PubMed ID: 18020612
[TBL] [Abstract][Full Text] [Related]
13. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.
Merlini PA; Ardissino D; Bauer KA; Oltrona L; Pezzano A; Bottasso B; Rosenberg RD; Mannucci PM
Arterioscler Thromb Vasc Biol; 1997 Jul; 17(7):1325-30. PubMed ID: 9261263
[TBL] [Abstract][Full Text] [Related]
14. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
Linder R; Oldgren J; Egberg N; Grip L; Larson G; Siegbahn A; Wallentin L
Eur Heart J; 1999 Apr; 20(7):506-18. PubMed ID: 10365287
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
[TBL] [Abstract][Full Text] [Related]
16. Desirudin: a review of its use in the management of thrombotic disorders.
Matheson AJ; Goa KL
Drugs; 2000 Sep; 60(3):679-700. PubMed ID: 11030473
[TBL] [Abstract][Full Text] [Related]
17. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin.
Zoldhelyi P; Bichler J; Owen WG; Grill DE; Fuster V; Mruk JS; Chesebro JH
Circulation; 1994 Dec; 90(6):2671-8. PubMed ID: 7994807
[TBL] [Abstract][Full Text] [Related]
18. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.
Serruys PW; Herrman JP; Simon R; Rutsch W; Bode C; Laarman GJ; van Dijk R; van den Bos AA; Umans VA; Fox KA
N Engl J Med; 1995 Sep; 333(12):757-63. PubMed ID: 7643882
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma.
Gast A; Tschopp TB
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):553-60. PubMed ID: 7578898
[TBL] [Abstract][Full Text] [Related]
20. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
